According to an exclusive poll of healthcare professionals worldwide, patients receive the best care in the emergency room between 6 a.m. and noon. The survey respondents were given four multiple-choice options — between midnight and 6 a.m., 6 a.m. to noon, noon to 6 p.m., and 6 p.m. to midnight — and 41% said that between 6 a.m. and noon is prime time for the best ER care.

This study analyzed 147 patients with hormone receptor-positive and HER2-positive metastatic breast cancer (HR+/HER2+ MBC) who received first-line chemotherapy and dual anti-HER2 therapy using a real-world registry dataset. The efficacy of adding endocrine therapy to dual anti-HER2 therapy after chemotherapy discontinuation was studied retrospectively. The researchers discovered that endocrine therapy resulted in statistically significant and clinically meaningful improvements in both PFS and overall survival outcomes. In the first-line treatment of HR+/HER2+ MBC, the current standard practice is to administer a CLEOPATRA trial-based regimen that includes taxane, pertuzumab, and trastuzumab until the best response is achieved and then discontinue chemotherapy. These findings, with a hazard ratio of 0.52 for overall survival with the addition of endocrine therapy, confirm that all patients with HR+/HER2+ MBC should receive endocrine therapy after achieving the best response with chemotherapy.

Immunotherapy combinations with activity in patients with microsatellite stable (MSS) metastatic colorectal cancer are needed, and the recommended phase 2 dose of RIN had a manageable safety profile and an overall response rate of 27.6%, a median progression-free survival of 4 months, and a median overall survival of 20 months in this nonrandomized clinical trial of 39 patients with metastatic colorectal cancer. Patients with no liver metastases received responses (overall response rate, 36.4%; median overall survival not reached).

The findings of this retrospective dual-center cohort study of diffuse malignant peritoneal mesothelioma (DMPM) patients suggest that pembrolizumab had clinical activity regardless of PD-L1 status or histology, though patients with nonepithelioid histology may have benefited more. The partial response rate of 21.0% and median OS of 20.9 months in this cohort with 75.0% epithelioid histology call for additional research to identify those most likely to respond to immunotherapy.

At a median follow-up of 24 months following initial PSMA PET scans, 73 of the 226 patients studied had clinical recurrence (CR). The 3-year CR-free rates in the 109-person metastasis-directed therapy (MDT) group were 51% and 28% in the no MDT group (117), respectively. Men who did not receive MDT had a significantly higher rate of distant metastases at CR than those who did (86% vs. 77%). The proportion of distant metastases was significantly lower in the MDT group (67% vs. 76%).

The US Bureau of Labor Statistics released job growth projections for the next decade, from 2021 to 2031. Nurse practitioners are expected to grow at a rate of 45% across all industries. Over the next ten years, the number of employed nurse practitioners is expected to increase from 246,700 to 359,400. Sadly, physicians are missing from the list, with the Association of American Medical Colleges projecting a shortage of 37,800 to 124,000 physicians by the year 2034.